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Abstract
Introduction: European treatment guidelines in persons with known coronary
heart disease (CHD) focus on adherence to antiplatelet therapy, β-blockers,
ACE/ARBs, and lipid-lowering agents, with goals for blood pressure (BP) of 
< 140/90 mm Hg and LDL cholesterol of < 3.0 mmol/l. Data on adherence to
these measures in Eastern Europe are limited.
Material and methods: The Third Republic of Srpska, Bosnia and Herzegovina,
Coronary Prevention Study (ROSCOPS III) was conducted in 2005-2006 at 
10 primary heath care centres in 601 patients (36% female, mean age 55 years)
with CHD including acute myocardial infarction or ischaemia, coronary artery
bypass graft, or angioplasty who were examined and interviewed at least  
6 months after the event. We examined the proportion of subjects on
recommended treatments and at goal for BP, LDL-C, and non-smoking. 
Results: The proportion of subjects on recommended treatments included 61%
for β-blockers, 79% for ACE/ARBs, 63% for lipid-lowering agents and 74% for
antiplatelet therapy. Only 30% of subjects were on all four of these treatments.
59% of subjects had BP at goal of < 140/90 mm Hg and 33% were controlled to
< 130/80 mm Hg, 41% for LDL-C, and 88% were non-smokers. Improvements
were seen in lipid-lowering and ACE/ARB drug use and non-smoking status from
an earlier survey (ROSCOPS II) in 2002-2003.
Conclusions: Our data show, despite improvement over recent years, that many
persons with CHD in the Republic of Srpska, Bosnia and Herzegovina are neither
on recommended treatments nor at target for BP and/or LDL-C. Improved efforts
targeted at both physicians and patients to address these issues are needed.
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Introduction
Coronary heart disease (CHD) remains a major cause of morbidity,
mortality and disability in Bosnia and Herzegovina and other Eastern
European countries and is an emerging epidemic. There is up to a 10-fold
difference in premature cardiovascular disease (CVD) mortality between
Western Europe and countries in Central and Eastern Europe, with the
highest mortality rates in the East European Countries. Cardiovascular
Corresponding author:
Dusko Vulic, MD, PhD
Center for Medical Research
Vuka Karadzica 6
78000 Banja Luka
Republic of Srpska,
Bosnia and Herzegovina
Phone: 38751241239
Fax: 38751241246
E-mail: 
dvulic@zdravljeisrce.com
Original research
1Department of Internal Medicine, University of Banja-Luka, Bosnia and Herzegovina
2Centre for Medical Research Banja-Luka, Bosnia and Herzegovina
3Heart Disease Prevention Program, Division of Cardiology, Department of Medicine,
University of California, Irvine, California, USA
Submitted: 31 December 2009
Accepted: 28 January 2010
Arch Med Sci 2010; 6, 2: 183-187
DOI: 10.5114/aoms.2010.13891
Copyright © 2010 Termedia & Banach184 Arch Med Sci 2, April / 2010
Dusko Vulic, Sasa Loncar, Milenko Krneta, Ranko Skrbic, Aleksandar Lazarevic, Brian T. Lee, Victor A. Lopez, Nathan D. Wong
disease mortality rates decreased by 2% in Western
countries and increased 6% in the East and parts
of Central Europe. In the former Yugoslavia and
Republic of Srpska/Bosnia and Herzegovina, after
a period of decreased CVD mortality from 1980 to
1990, there have been increases in mortality due
to CVD.
Risk factor control and lifestyle changes are the
foundation of secondary prevention efforts. Over
the past 11 years, guideline panels, including those
from the European Society of Cardiology [1],
American Heart Association, and American College
of Cardiology [2], have developed a series of
recommendations for therapy and clinical
management of risk factors in persons with CHD.
Previous studies have shown that cardiovascular
risk factors among CHD patients are poorly
controlled [3] and often remain above target levels,
despite improvements over recent years [4].
Lifestyle, goal values of risk factors, and therapeutic
goals set by recommendations of the Joint
European Societies for coronary disease prevention
in clinical practice are not achieved by most
patients throughout Europe [1, 5]. Many national
multicentre studies have shown results similar to
those in EUROASPIRE I (1995/96), EUROASPIRE II
(1999/2000), and EUROASPIRE III (2006/2007) 
[3, 6, 7].
Data are lacking regarding the recent status of
adherence to recommended treatments and risk
factor goal attainment among CHD patients,
particularly in Eastern and Southeastern European
countries. We assessed the extent of CHD risk factor
control, goal attainment, and adherence to
recommended treatments in adults of the Republic
of Srpska, Bosnia and Herzegovina with known CHD
from a recent examination following diagnosis of
CHD.
Material and methods
We identified 601 adults (36% female) 18 years
and older with known CHD between December
2005 and December 2006 in 10 primary health care
centres in selected areas of the Republic of Srpska,
a state entity comprising 1.4 million people and
encompassing the northern part of Bosnia and
Herzegovina. General practitioners performed
interviews and examinations at least 6 months
after the event. Coronary heart disease was verified
by medical records based on diagnosis including
acute myocardial infarction (ST elevation and non-
ST elevation MI) (47%, n = 283), elective or
emergency coronary artery bypass graft (CABG)
(24%, n = 144), acute myocardial ischaemia but no
evidence of infarction (troponin negative) (21%, 
n = 126) or elective or emergency percutaneous
transluminal coronary angioplasty (PTCA) (8%, 
n = 48). We examined overall goal attainment for
blood pressure (BP) and low-density lipoprotein
cholesterol (LDL-C), as defined by the European
Society of Cardiology Third Joint Task Force of
European and other societies on Cardiovascular
Disease Prevention in Clinical Practice. Goal
attainment included BP below 140/90 mm Hg
(although results are also presented according to
recently released recommendations for a lower goal
of below 130/80 mm Hg) [8], LDL-C less than 
< 3 mmol/l (115 mg/dl) and non-smoking status.
Treatment for β-blockers, renin-angiotensin
blockade (ACE/ARBs) medications, antiplatelets, and
lipid-lowering agents were identified by visual
inspection of medications brought in by subjects
or from chart review.
We analysed the attainment of goals and
adherence to treatment across gender. We
compared treatment patterns and control of BP and
LDL-C to ROSCOPS II, a study of similar metho  -
dology conducted in 363 patients (21% female,
mean age 52 years) among 7 primary health centres
in 2002-2003 [9, 10].
Measurements
Blood pressure was measured using a mercury
sphygmomanometer and taking the average of two
readings from the examination. Total cholesterol
and triglycerides were measured enzymatically. How
densitylipoprotein cholesterol was measured
directly in the serum, and LDL-C levels were
calculated using the Friedewald formula.
Statistical analysis
The Chi-square test of proportions was used to
compare proportions of those on the different
treatments or at goal for LDL-C, BP, and non-
smoking status across gender, and for each of these
measures between ROSCOPS II and ROSCOPS III. 
Results
The proportions on recommended treatments
for ROSCOPS III were 61% for β-blockers, 79% for
ACE/ARBs, 63% for lipid-lowering agents, and 74%
for antiplatelet therapy (Table I). Only 30% of
subjects were on all four of these treatments.
Significantly greater proportions of men were on
lipid-lowering and antiplatelet therapy than women.
The proportions on recommended treatments for
ROSCOPS II were 59% for β-blockers, 53% for
ACE/ARBs, 28% for lipid-lowering agents, and 70%
for antiplatelet therapy. Only about 9% were on all
four recommended treatments (Table I). Overall,
treatment rates with lipid-lowering agents 
(p < 0.01), ACE/ARBs (p < 0.01) and antiplatelets 
(p < 0.05 in males) as well as for all four
recommended treatments (p < 0.01) were greater
in ROSCOPS III than in ROSCOPS II. Similar resultsArch Med Sci 2, April / 2010 185
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were observed when analyses were stratified by
gender (Table I).
Overall, in ROSCOPS III the proportion of CHD
participants at goal was 59% for BP (33% based on
SBP/DBP 130/80 mm Hg goal), 41% for LDL-C, and
88% were not smoking (Table II). Compared to
ROSCOPS II, there was similar control for BP (58 vs.
59%) and LDL-C (42 vs. 41%), but the proportion of
non-smokers was improved (88 vs. 72%) due to
dramatically less smoking in men. There was also
better LDL-C control in females (p < 0.01) in
ROSCOPS II and better BP control in males in
ROSCOPS III. While two-thirds to three-fourths of
patients were on recommended BP and statin
therapies, with recent increases in lipid-lowering
medication and ACE/ARB use, 41 and 59% of the
population remain inadequately controlled for BP
and LDL-C, respectively.
Discussion
Our study is unique in being among the most
recent studies of treatment adherence and risk
factor control in CHD patients in Southeastern
Europe. In the Republic of Srpska, Bosnia and
Herzegovina, we report that many persons with
CHD in 2005-2006 fall short of the European
Guidelines’ recommended goals for BP and lipids.
However, our reported treatment rates for
cardioprotective drugs (ACE/ARBs, β-blockers, lipid-
lowering agents, and antiplatelets) are higher than
reports from previous investigations in European
clinical populations that have examined CHD
patients [1, 11]. We also report significant
improvement in ROSCOPS III since ROSCOPS II for
ACE/ARBs, lipid-lowering agents, antiplatelets and
all four despite no improvement in β-blocker use.
Also, there were more persons on recommended treat  -
ments when comparing our study to ROSCOPS I,
a study done in 2001 where 430 CHD patients were
surveyed and only 45% of subjects were on
antiplatelets, 23% on β-blockers, 5% on lipid-
lowering agents, and 62% on ACE/ARBs [10].
However, the proportion at goal for BP has not
improved in ROSCOPS III and for LDL-C has actually
Proportions (%) ROSCOPS II‡ ROSCOPS III‡
Male Female Total Male Female Total
β-Blockers 59.2 57.9 59.0 62.8 59.0 61.4
(287) (76) (363) (384) (217) (601)
Lipid-lowering agents 28.6 26.3 28.1 68.5**†† 52.1**  62.6**
(287) (76) (363) (384) (217) (601)
Antiplatelets 71.8 65.8 70.0 77.9*†† 66.4 73.7
(287) (76) (363) (384) (217) (601)
ACE/ARBs 51.9 56.6 52.9 78.1** 80.6** 79.0**
(287) (76) (363) (384) (217) (601)
All four 8.7 7.9 8.5 32.8** 26.6** 30.4**
(287) (76) (363) (384) (217) (601)
ROSCOPS – Republic of Srpska Coronary Prevention Study, ACE/ARBs – angiotensin receptor blockade medications, ‡total sample sizes available
for each measure are indicated in parentheses, *p < 0.05, **p < 0.01 when compared to ROSCOPS II, p < 0.05, ††p < 0.01 comparing males and
females
Table I. Proportions of patients with coronary heart disease on recommended therapies
Proportions (%) ROSCOPS II‡ ROSCOPS III‡
Male Female Total Male Female Total
Non-smokers 67.9†† 85.5 71.6 90.4**†† 82.5 87.6**
(287) (76) (363) (376) (212) (588)
BP < 140/90 mm Hg 57.5 57.9 57.6 63.9 50.5 59.1
(287) (76) (363) (324) (182) (506)
LDL-C < 3.0 mmol/l  37.6†† 57.9 41.9 44.1 35.6** 41.0
(115 mg/dl) (287) (76) (363) (161) (90) (251)
ROSCOPS – Republic of Srpska Coronary Prevention Study, BP – blood pressure, LDL-C – low-density lipoprotein cholesterol, ‡total sample sizes
available for each measure are indicated in parentheses, *p < 0.05, **p < 0.01 when compared to ROSCOPS II, †p < 0.05, ††p < 0.01 comparing
males and females
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worsened in women compared to ROSCOPS II. The
fact that many patients are not at goal for BP and
LDL-C indicates the need for adequate dosing
and/or combination therapy of lipid and BP control
in such individuals from the onset of therapeutic
intervention and working with patients on
adherence to treatment.
Our rates of lipid control indicate improvement
from earlier reports in CHD patients. The American
College of Cardiology Evaluation of Preventive
Therapeutics (ACCEPT) study in 1998 showed that
only about 24% of CHD patients in the USA had
LDL-C treated to a target value less than < 3 mmol/l
[12]. Our BP control rate of 59.1% can be compared
to the lower rates of control of 41, 41.2, and 38.7%
reported earlier in the EUROASPIRE I, II, and III
studies, respectively [11-13]. However, based on 
the newly released recommended targets of 
< 130/80 mm Hg for patients with CHD in a recent
statement from the American Heart Association [8],
only 33% would be considered to be at goal,
indicating the further need for use of combination
or intensive therapeutic approaches. From the
EUROASPIRE I, II, and III studies, there has been an
increased use of antiplatelets (80, 84 and 93%,
respectively),  β-blockers (56, 69, and 85%,
respectively), ACE/ARBs (31, 49, and 75%,
respectively) and lipid-lowering medication (18, 57,
and 87%, respectively) in participants with a history
of CHD [3, 6, 7]. There was no change in BP control
despite increased use of anti-hypertensive
medication and there was continued improvement
in lipid control with increased use of statins.
However, preventive cardiology practice can be
improved, as was shown in the PREVESE studies.
The first PREVESE study was conducted in Spain in
1994, and then in 1998, in patients after an event
of myocardial infarction. Significant changes in the
use of medications were shown in a one-year time
span since discharge from hospital; there was
increased use of β-blockers from 38 to 42% and
significant increase in use of statins from 29 to 57%
during this period. At the end of the one-year
follow-up, only 3.6% of CHD patients smoked and
90% of them reached the BP goals [13]. Our study
as well as EUROASPIRE I, II, and III among persons
with CHD shows improvements in the use of
cardioprotective drugs from earlier reports; however,
many persons still remain inadequately controlled.
In addition, our study shows an increasing number
of CHD patients who are non-smokers from
ROSCOPS II to ROSCOPS III (72 vs. 88%,
respectively). EUROASPIRE I, II, and III also showed
a small increase in the number of non-smokers (80,
79, and 83% respectively) [3, 6, 7]. These studies
demonstrate that under conventionally guided
management, a large number of CHD patients are
left untreated by cardioprotective drugs, despite an
increase in use. In comparison to recent reports,
the majority of patients are still not achieving BP
and cholesterol targets [14, 15]. The findings of
EUROACTION investigators suggest that multi  -
disciplinary efforts can effectively alter patient
behaviour and modify risk factors [16].
Our study has several strengths and limitations.
While we standardized procedures for mea  sure  -
ment of risk factors and evaluations of medical
history, not all participants had risk factor
measurements available; hence estimates could be
biased if those with missing information for risk
factors were not representative of the cohort at
large. Also, the time from the CHD event to the time
of follow-up examination visit was variable and
compliance may vary with time, possibly being
lower the longer the time that has passed since the
event. Importantly, however, CHD event status was
verified by a physician medical record review.
In conclusion, a substantial majority of CHD
patients in the Republic of Srpska, Bosnia and
Herzegovina still are not optimally treated for BP
or LDL-C; however, there have been recent
improvements in treatment, particularly lipid-
lowering medication and ACE inhibitors/ARBs.
Further education of patients and providers in the
appropriate use (including effective dosages and
use of combination therapies) of cardioprotective
drugs is needed. There is a need for uniform
surveillance of coronary patients who need the
support of hospitals, rehabilitation centres and
general practitioners for the purpose of appropriate
implementation of secondary prevention measures.
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